PIK3CD and acute leukemia: Moreover, several studies have highlighted that both PI3K and mTOR modulators could synergize with a wide range of drugs that are currently in use for treating acute leukemias, including chemotherapeutic drugs [108; 192, 193; 204], glucocorticoids [205-206], histone deacetylase inhibitors [207], ionizing radiation [208], proteasome inhibitors [208], all-trans-retinoic acid [193], and arsenic trioxide (As2O3) [209, 210].